Can You Combine Magic Truffles with SSRIs or Antidepressants?

The serotonin system: 5-HT2A and reuptake

Psilocybin is a prodrug. Your body has to convert it before it becomes active. The active compound is psilocin. Psilocin binds to the 5-HT2A serotonin receptor and mimics serotonin's action there (Vollenweider and Preller, 2020; Nichols, 2016). That receptor system is responsible for a large part of what makes a psychedelic experience so intense: colour, meaning, shifts in sense of self.

SSRIs work on the same system in a different way. SSRI stands for selective serotonin reuptake inhibitor. The medication keeps nerve cells from quickly reabsorbing serotonin after release. More serotonin stays in the synaptic cleft. With chronic use (weeks to months), your brain adapts: 5-HT2A receptors gradually become less sensitive. This is called downregulation.

Why SSRIs blunt the effects of truffles

When 5-HT2A receptors are less sensitive, there's less to activate. Psilocin can still bind, and the receptor responds less strongly. The result: your trip is muted, or feels different than it would without an SSRI.

And here it gets interesting. A randomised study from 2022 (Becker et al., DOI: 10.1002/cpt.2487) gave healthy participants fourteen days of escitalopram or placebo, then 25 mg of psilocybin. The positive mood effects didn't clearly differ. What did differ: less anxiety, less heart-rate increase, fewer unpleasant side effects. That's striking. The familiar "SSRIs block the trip" story isn't quite right.

Older data from Bonson et al. (1996) and the systematic review by Sarparast et al. (2022) describe more pronounced blunting with longer SSRI use. The picture isn't uniform. What we can say: short-term use at a low SSRI dose probably blunts less than years of chronic use at a high dose. Person-to-person variation is wide.

Serotonin syndrome: rare, but recognise it

Serotonin syndrome is an acute condition that develops when there's too much serotonin activity in the body (Boyer and Shannon, NEJM 2005). The classic triad of symptoms: altered mental state (confusion, agitation), autonomic disturbance (high fever, rapid heartbeat, blood pressure swings, sweating), and neuromuscular problems (tremor, muscle twitches, hyperreflexia, clonus). In severe cases it can be life-threatening.

How big is this risk with truffles plus an SSRI? In the scientific literature, extremely small. The systematic review by Halman et al. (2024) looked at 52 studies of classic psychedelics and found no serious adverse events for the psilocybin-plus-SSRI combination outside a few isolated case reports. What can still trigger it? High psilocybin doses, polypharmacy (multiple medications at once), and especially when an SSRI or SNRI sits on top of an MAOI — that's the combination the literature flags for serotonin syndrome, because both psilocin and the SSRI/SNRI feed serotonergic input the MAOI can no longer clear. MAOI plus truffles alone is a different picture; more on that below.

What do you do if you recognise the symptoms? Call 112. No delay. No "I'll wait it out." Serotonin syndrome is an emergency.

Reduced and unpredictable effect

If you're taking truffles to reach something specific (a breakthrough, a deeper experience, integration of something old), a blunted trip probably isn't what you want. And "blunted" isn't the same as "safer." It can also mean you dose higher to reach somewhere, you sit longer in a grey in-between space, or your trip unfolds differently than expected and is harder to integrate afterward.

Some people decide to taper off under their doctor's guidance first and then plan a session afterward. That conversation belongs in the consulting room, not here.

SSRIs: blunting, no acute crisis

With most SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram), the dominant effect is blunting of the trip. Acute risks are small at normal dosages. Pharmacokinetics differ per medication (Hiemke and Härtter, 2000):

Sertraline (Zoloft): half-life around 26 hours. Clinical trials usually use a two-week washout.

Fluoxetine (Prozac): this one is the exception. The parent compound has a half-life of a few days, and the active metabolite norfluoxetine can stick around for four to sixteen days. Researchers therefore use a five-week or longer washout for fluoxetine.

Paroxetine (Seroxat): half-life around 21 hours. Notorious for severe withdrawal symptoms when stopped abruptly.

Citalopram and escitalopram: half-lives of 30 to 35 hours.

SNRIs: similar, sometimes more pronounced

Venlafaxine (Effexor) and duloxetine inhibit both serotonin and noradrenaline reuptake. The interaction with psilocybin resembles that of SSRIs, and the dual action can make it slightly more pronounced. Half-lives are short: venlafaxine around 5 hours for the parent compound, 11 hours for the active metabolite O-desmethylvenlafaxine.

MAOIs: a different category

Here the story changes, and it's worth being precise about how. MAOIs (like tranylcypromine and phenelzine) block monoamine oxidase. MAO-A is one of the routes the body uses to break down psilocin. Choke that route off and psilocin sticks around longer; the effect becomes stronger and lasts longer. This is the same mechanism that makes ayahuasca work — harmine in the brew is a natural MAOI alongside DMT (Callaway and Grob, 1998). Without that MAOI, oral DMT is broken down before it can do much centrally.

What this is not: classical serotonin syndrome in the SSRI-plus-MAOI sense. Serotonin syndrome is driven by excess synaptic serotonin — a presynaptic story of too much release, too little reuptake, or too little breakdown combined with another serotonergic input. Psilocin is a direct 5-HT2A receptor agonist: it activates the receptor; it doesn't raise synaptic serotonin the way an SSRI or MDMA does. The mechanism that makes MAOI plus SSRI dangerous — two presynaptic inputs feeding the serotonin system — isn't in play here. The Halman 2024 review does classify MAOIs with classic psychedelics as a pharmacodynamic interaction warranting caution, but it does not document significant serotonin-syndrome incidence specific to psilocybin plus MAOI alone.

What it is: unpredictable potentiation in a group of people who are on heavy antidepressants for a reason. Classic MAOIs are rarely prescribed in the Netherlands these days, but if you take them or are considering them, the advice still stands: don't combine them with truffles. Not primarily because of acute serotonin syndrome, but because the trip becomes stronger and longer than you bargained for, in a context that's rarely the right setting for that kind of amplification. The genuine high-risk picture in this family appears once an SSRI or SNRI is added — that's where presynaptic serotonergic input stacks on top of the inhibited breakdown. It's why a serious ayahuasca facilitator always asks whether you're on an SSRI and, if you are, wants you to taper off under medical supervision first — not because ayahuasca alone plus SSRI is safe, but because MAO inhibition (in the brew) plus DMT plus SSRI is exactly the mechanism where things go wrong.

Lithium: not an antidepressant, still concerning

Lithium is a mood stabiliser, used mostly for bipolar disorder and as augmentation in treatment-resistant depression. An analysis by Nayak et al. (2021) reviewed online experience reports on Erowid and found that roughly half of the reported combinations of classic psychedelics with lithium involved seizures (29 out of 62 reports). With lamotrigine, another mood stabiliser, no seizures appeared in 34 reports.

The sample is self-reported cases, not clinical confirmation. The signal is strong enough to avoid the combination. Lithium plus classic psychedelics isn't a home experiment. Skip it.

Half-lives in numbers

Clinical trials typically use a washout period of five times the half-life, so the drug is practically cleared. For sertraline that comes down to about two weeks. For fluoxetine, because of the long-lived metabolite, five weeks or longer. For other SSRIs you sit somewhere between.

These numbers are pharmacokinetic context. They aren't taper advice.

Tapering isn't a solo job

Stopping antidepressants abruptly can cause withdrawal symptoms (dizziness, "electric shocks" in the head, sleep disturbances, return of depression or anxiety). Paroxetine and venlafaxine in particular. A relapse into depression is no small thing. Tapering needs a schedule that fits your medication, dose, and overall health.

Talk to your prescribing doctor. If they aren't familiar with psilocybin pharmacology, you can ask them to consult the Jellinek interaction tool or to reach out to a colleague who has the experience. A good doctor doesn't get defensive about that.

Harm reduction: if you do combine

Sometimes someone is going to do it anyway. Not out of recklessness or naivety. With a considered choice I can respect, even when I'd advise against it. Before the practical tips, one thing to fold into that consideration: this choice is never only yours. If it goes wrong — serotonin syndrome, an acute crisis, a 112 call — it pulls people around you into a night that wasn't theirs. A family member, a flatmate, an ER nurse working without context. And psychedelica.nl exists in a country where the legal room for truffles is still thin. Every avoidable crisis with truffles that hits the news is paid for by everyone hoping for more room next year — facilitators who see their work pushed further underground, researchers whose proposals are delayed another two years, people for whom psychedelics could be a serious path. Not to stop you — you've already made the call — but to weigh what else is on the table besides yourself. For that situation:

Lower the dose. A smaller dose is less of a load on the system and gives you more room to notice how your body reacts. Start low. Don't take a regular "full" dose if you're on SSRIs.

Setting and trip sitter. Don't do it alone, and definitely not by yourself if you're on antidepressants. A sober, trusted trip sitter who recognises the signs of serotonin syndrome (high fever, muscle twitches, strong heart pounding, confusion) is basic safety. Not a luxury. Keep your phone within reach.

When to call 112. With high fever, severe muscle spasms, confusion, or heart pounding that doesn't ease: call. Tell the operator what you took and what medication you use. Honest and concrete. First responders can't work with half a story.

This is harm reduction. Not encouragement. If reading this list makes you uneasy, take that concern seriously.

The Dutch context: legality and support

Truffles are legal in the Netherlands (see our article on the legal difference between truffles and magic mushrooms). Legal doesn't mean medically regulated. There's no Dutch guideline that tells doctors how to handle patients on SSRIs who also want to use truffles. That category formally doesn't exist.

What does exist: harm-reduction organisations holding the general line of "don't combine, and never stop your medication on your own." Jellinek has an interaction tool and a phone helpline (088-5051220, office hours). The Trimbos Institute publishes fact sheets on psilocybin and truffles via drugsinfo.nl and runs a general drug info line (0900-1995). For suicide prevention 113 (0800-0113, free, 24/7). For acute medical crisis 112.

In practice, some ceremony facilitators screen carefully for medication, others don't. A serious facilitator asks about your history, your current medication, and turns you away or schedules you later if the combination isn't safe. Ask explicitly before you sign up. "We don't work with people on SSRIs, come back when you've tapered in agreement with your doctor" is professional care, not rejection.

The pharmacology is complex and your situation is unique. Your doctor doesn't always have the answers about psychedelics, and the psychedelic scene doesn't always have the answers about your specific medication. Between those two gaps, you have to draw your own line.

Sources

1. Vollenweider FX, Preller KH (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience 21: 611-624. DOI: 10.1038/s41583-020-0367-2

2. Nichols DE (2016). Psychedelics. Pharmacological Reviews 68(2): 264-355. DOI: 10.1124/pr.115.011478

3. Bonson KR, Buckholtz JW, Murphy DL (1996). Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6): 425-436. DOI: 10.1016/0893-133X(95)00145-4

4. Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME (2022). Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology & Therapeutics 111(4): 886-895. DOI: 10.1002/cpt.2487

5. Sarparast A, Thomas K, Malcolm B, Stauffer CS (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 239(6): 1945-1976. DOI: 10.1007/s00213-022-06083-y

6. Halman A, Kong G, Sarris J, Perkins D (2024). Drug-drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol 38(1): 3-18. DOI: 10.1177/02698811231211219

7. Boyer EW, Shannon M (2005). The Serotonin Syndrome. New England Journal of Medicine 352(11): 1112-1120. DOI: 10.1056/NEJMra041867

8. Callaway JC, Grob CS (1998). Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse reactions. J Psychoactive Drugs 30(4): 367-369. DOI: 10.1080/02791072.1998.10399712

9. Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR (2021). Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. Pharmacopsychiatry 54(5): 240-245. DOI: 10.1055/a-1524-2794

10. Hiemke C, Härtter S (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & Therapeutics 85(1): 11-28. DOI: 10.1016/S0163-7258(99)00048-0

11. Brown RT, Nicholas CR, Cozzi NV, et al. (2017). Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clinical Pharmacokinetics 56(12): 1543-1554. DOI: 10.1007/s40262-017-0540-6

12. Jellinek - Vraag en Antwoord. https://www.jellinek.nl/vraag-en-antwoord/

13. Trimbos-instituut / Drugsinfo. https://www.drugsinfo.nl/